Helicobacter pylori infection
Conditions
Interventions
VA (VPZ 20 mg, taken twice daily before meals, and AMO 1000 mg, taken three times daily (30 minutes after meals), for a duration of 14 days.):None
VBQT (VPZ 20 mg, AMO 1000 mg, clarithromycin 500 mg, and bismuth potassium citrate 220 mg. Vonoprazan and bismuth were taken 30 minutes before meals, while AMO and clarithromycin were taken immediatel
Sponsors
Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients aged 18-80 years who were diagnosed with H. pylori infection through at least one of the following methods: carbon-13/14 urea breath test (13C/14C-UBT), H. pylori antibody detection, pathological examination, and received the first-line eradication therapy of VA regimen or VBQT regimen were eligible for the clinical study.
Exclusion criteria
Exclusion criteria: (1) Patients receiving salvage therapy; (2) Patients who received PPI, P-CAB, bismuth, or antibiotic therapy within the past 4 weeks; (3) Patients who have undergone gastric resection; (4) Patients who are pregnant, breastfeeding, or allergic to the study drugs; (5) Patients with severe cardiovascular, respiratory, endocrine, renal, hepatic, or hematological diseases; (6) Patients with severe neurological or psychiatric disorders; (7) Patients with incomplete follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Helicobacter pylori eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| adverse events; | — |
Countries
China
Contacts
Public ContactLiu Zhu
Department of Gastroenterology, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University
Outcome results
None listed